NDT Pharmaceuticals Inc.
NDTP · OTC
12/31/2024 | 12/31/2023 | 12/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.35 | 0.00 | 0.68 | 0.16 |
| FCF Yield | 0.00% | -0.18% | 0.00% | 0.00% |
| EV / EBITDA | 0.00 | 110.27 | -306.65 | -197.09 |
| Quality | ||||
| ROIC | 0.00% | -24.88% | -3.02% | -4.56% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.22 | 1.00 | 0.06 | 0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.01 | -282.26 | -181.41 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |